The only part of the update I am interested in at this stage:
A new customer engagement in a Continuous Glucose Monitoring solution has produced a sensor expected to ramp materially late in FY21. The SARS-CoV-2 sensor developed in conjunction with NanoDx has progressed through the R&D phase and the final product is now in the hands of NanoDx. The Group has engaged in a material agreement that will be fully disclosed once the sensor reaches FDA approval. The Group was also able to engage and develop a laser-based sensor that hit key milestones late in the first half of FY21 to ensure a production level product could be attained and potentially ramp in FY22.
- Forums
- ASX - By Stock
- SE1
- Ann: Half Year Accounts - Appendix 4D
Ann: Half Year Accounts - Appendix 4D, page-2
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SE1 (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
CC9
CHARIOT CORPORATION LTD
MD - Shanthar Pathmanathan, Geologist - David Trabert
MD - Shanthar Pathmanathan
Geologist - David Trabert
SPONSORED BY The Market Online